Man Group
TRDA icon

Man Group’s Entrada Therapeutics TRDA Stock Holding History

Man Group’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,805
Closed -$113K – 2474
2025
Q2 		$113K Buy
+16,805
New +$135K ﹤0.01% 2116
2024
Q3 		– Sell
-17,249
Closed -$246K – 2206
2024
Q2 		$246K Buy
17,249
+440
+3% +$6.25K ﹤0.01% 1836
2024
Q1 		$238K Buy
+16,809
New +$238K ﹤0.01% 1980
2023
Q3 		– Sell
-14,466
Closed -$219K – 2151
2023
Q2 		$219K Buy
+14,466
New +$199K ﹤0.01% 1802
2023
Q1 		– Hold
0
– – – 1853

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Man Group's TRDA Position: Q3 2025 in Review

Man Group sold out of Entrada Therapeutics (TRDA) in Q3 2025, closing a stake of 16,805 shares — an estimated $113K sold.

Man Group first reported a position in TRDA in Q2 2023 and held it in 4 quarters. The position peaked at $246K in Q2 2024. 117 funds tracked by Wall St. Rank hold TRDA as of Q3 2025.

  • Man Group reported no remaining Entrada Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Man Group sold 16,805 Entrada Therapeutics shares in Q3 2025, an estimated $113K.
  • Man Group first reported a position in Entrada Therapeutics in Q2 2023 and held it in 4 quarters.
  • Man Group's Entrada Therapeutics position peaked at $246K in Q2 2024.
  • 117 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2025.

Based on Man Group's 13F filing for Q3 2025, filed 14 Nov 2025.